Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Press Release: Helsinn Announces the Launch of Adlumiz(R) (anamorelin) for the Treatment of Cancer Cachexia in Japan

04/21/2021 | 02:30am EDT
 
   Helsinn Announces the Launch of Adlumiz(R) (anamorelin) for the 
Treatment of Cancer Cachexia in Japan 
 
   Lugano, Switzerland, April 21, 2021 -- Helsinn, a Swiss pharmaceutical 
group focused on building quality cancer care and rare disease products, 
today announces the first launch of Adlumiz(R) (anamorelin) for the 
treatment of cancer cachexia in malignant non-small cell lung cancer, 
gastric cancer, pancreatic cancer and colorectal cancer in Japan, 
through its partner Ono Pharmaceutical. 
 
   Cancer cachexia is a complex metabolic disorder syndrome, characterized 
by decreased body weight (especially decreased muscle mass) and anorexia 
associated with cancer. This condition is a common complication of 
cancer, that can affect up to 80% of patients with advanced cancer. It 
has been well documented that cancer cachexia has a significant impact 
on patients' quality of life and prognosis. Adlumiz(R) (anamorelin), as 
approved by the Japanese Health Authorities, has shown efficacy in 
increasing body weight, muscle mass, as well as appetite in cancer 
cachexia patients. The risks identified in association with anamorelin 
are justified by the anticipated benefits that may be afforded to adult 
cancer patients. 
 
   Helsinn recently announced the approval of Adlumiz(R) (anamorelin) by 
the Japanese Minister of Health, Labour and Welfare based on results 
from two clinical studies conducted in Japan in patients with cancer 
cachexia in the following malignant tumors: non-small cell lung cancer, 
gastric cancer, pancreatic cancer, and colorectal cancer. 
 
   Ono Pharmaceutical, Helsinn's license partner, has exclusive rights to 
develop and commercialize the product in Japan, South Korea and Taiwan. 
Helsinn retains full rights in the rest of the world. 
 
   Development of anamorelin is ongoing internationally, through two phase 
III SCALA studies being conducted in the US, EU, Russia and Australia 
for adult patients with advanced non-small cell lung cancer for 
treatment of malignancy associated weight loss and anorexia. Further 
details on the two trials can be found on clinicaltrials.gov under: 
 
 
   -- ANAM-17-20: https://clinicaltrials.gov/ct2/show/NCT03743051 
 
   -- ANAM-17-21: https://clinicaltrials.gov/ct2/show/NCT03743064 
 
 
   Riccardo Braglia, Helsinn Group Vice Chairman and CEO commented: "I am 
proud that we are able to announce the launch of Adlumiz(R) (anamorelin) 
in Japan, following the hard work and dedication of the Helsinn team 
around the world. We are pleased to be able to offer this important 
treatment to cancer patients in the region, in close collaboration with 
Ono Pharmaceutical." 
 
   Sergio Cantoreggi, Helsinn Group Chief Scientific Officer commented: "We 
are thrilled to see the first commercial launch of Adlumiz(R) 
(anamorelin) in Japan and look forward to updating the market on the 
Phase III SCALA studies taking place in the US, EU, Russia and Australia 
which we hope will enable us to bring the treatment to more and more 
patients globally." 
 
   About Adlumiz(R) (anamorelin) 
 
   Anamorelin is a selective, novel, orally active ghrelin receptor 
agonist. Ghrelin is an endogenous peptide primarily secreted by the 
stomach. Upon binding to its receptor, ghrelin stimulates multiple 
pathways in the positive regulation of body weight, muscle mass, 
appetite and metabolism. 
 
   About the Helsinn Group 
 
   Helsinn is a privately-owned Swiss Pharma Company which, since 1976, has 
been improving the lives of patients, guided by core family values of 
respect, integrity and quality. The Group has an extensive portfolio of 
marketed innovative cancer and rare disease therapies, a robust drug 
development pipeline and ambitions to further accelerate its growth 
through in-licensing and acquisitions to address unmet medical needs. 
Helsinn operates a unique integrated licensing business model, achieving 
success with long-standing partners in 190 countries, who share our 
values. The Group's pharmaceutical business, (Helsinn Healthcare) is 
headquartered in Lugano, Switzerland with operating subsidiaries in the 
U.S. (Helsinn Therapeutics US) and China (Helsinn Pharmaceuticals China) 
which market the Group's products directly in these countries. The Group 
has additional operating subsidiaries in Switzerland (Helsinn Advanced 
Synthesis, an active pharmaceutical ingredient manufacturer) and Ireland 
(Helsinn Birex Pharmaceuticals, a drug product manufacturer). 3B Future 
Health Fund (formerly known as Helsinn Investment Fund) was created to 
enhance the future of healthcare by providing funding and strategic 
support to innovative companies. 
 
   Helsinn Group plays an active and central role in promoting social 
transformation in favor of people and the environment. Corporate social 
responsibility is at the heart of everything we do which is reinforced 
in the company's strategic plan by a commitment to sustainable growth. 
 
   To learn more about Helsinn Group please visit www.helsinn.com 
 
   About Ono Pharmaceutical Co., Ltd. 
 
   Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented 
pharmaceutical company committed to creating innovative medicines in 
specific areas. ONO focuses its research on the oncology, immunology, 
neurology and specialty research with high medical needs as priority 
areas for discovery and development of innovative medicines. For further 
information, please visit the company's website at www.ono-pharma.com/. 
 
   Helsinn Group Media Contact: 
 
   Paola Bonvicini 
 
   Group Head of Communication 
 
   Lugano, Switzerland 
 
   Tel.: +41 91-985-21-21 
 
   Info-HHC@helsinn.com 
https://www.globenewswire.com/Tracker?data=aHoflxzCjxkUHnvU76er3-fOHhQxdbNwMhdyfc7dbxeDiHG7r9TwcgLuTtaDJK65vKL1I_NLfzPbksKnrScTwqGImfrjJwky_-Z753M74pU= 
 
 
   For more information, please visit 
https://www.globenewswire.com/Tracker?data=tgvLiMlqkbGJQyBR42tZOvHqw7RfomjPaJJW2lpjiu2LqvQZxrLiH1E11o8XH74NZ6NGAsh22Q7y6oa5yEkaSw== 
www.helsinn.com and follow us on 
https://www.globenewswire.com/Tracker?data=neINkPeeOpZVg1luJRGAhfLaWF3IT4muqbBZ35j6mtaA6_zxvpxlcY0cD0hc5pvvuoAj7eGR0FsRbw_T-wGNew== 
Twitter, 
https://www.globenewswire.com/Tracker?data=3sUOv2wfM2rrhxnhgwuMqSmbTYwa96kopKIBBU6PHjXKKKViuGPkVZsh43qzmbfz0lLRfESAZsaJMjiJW24yJEX8dVeSIkrZU5h-BDgnNB0= 
LinkedIn and 
https://www.globenewswire.com/Tracker?data=5umkC1RKoOGd1l82oohmnDdtu7Yu9Ybp8HJkxgIi3ZRMIEIrcw-rIXVkel2CNiPyzt-O_8e7zel0OVWY__24Wg== 
Vimeo 
 
 
 
 

(END) Dow Jones Newswires

April 21, 2021 02:30 ET (06:30 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL 0.62% 35151.01 Delayed Quote.14.55%
MSCI TAIWAN (STRD) 1.49% 695.372 Real-time Quote.14.63%
ONO PHARMACEUTICAL CO., LTD. 0.82% 2528.5 End-of-day quote.-18.65%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) -0.50% 73.0475 Delayed Quote.-0.12%
Latest news "Companies"
01:30pCRMD INVESTOR FILING DEADLINE : Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against CorMedix Inc.
PR
01:30pPARIS REALTY FUND : Half-year Results 2021
AN
01:29pDYNATRACE : Storage handling improvements increase retention of transaction data for Dynatrace Managed
PU
01:29pECA, ITFC hold joint, AfCFTA training to facilitate Sudanese exports to the African market
PU
01:29pAMAZON DEMAND SIDEáPLATFORM (DSP) : How to UseáProgrammatic Advertising on Amazon
PU
01:29pADUX : First-Half 2021 Results
PU
01:29pQUALCOMM : New book by Qualcomm experts explains the fundamentals of 5G communications
PU
01:29pFATHOM : Going Live on Social Media
PU
01:29pSLC AGRÍCOLA S A : Analysts say imports needed to meet corn demand in 2022
PU
01:29pPortugal's EDP reports 9% rise in first-half profit
RE
Latest news "Companies"